Home » BioClinica Reports Flat Earnings, Adjusts 2010 EPS Guidance
BioClinica Reports Flat Earnings, Adjusts 2010 EPS Guidance
May 5, 2010
BioClinica’s first quarter 2010 earnings were flat compared with the same period 2009, with service revenues of $14.7 million. First quarter revenues last year were $14.5 million. Net income was $711,000, or $0.05 per diluted share, compared with $786,000, or $0.05 per diluted share for Q1 2009.
The company, which acquired clinical trial management software company TranSenda a month ago, reiterated its full-year 2010 service revenue forecast of $61 million to $65 million, but revised its earnings per share estimate to be in the range $0.23 to $0.27 per share (down from $0.25 to $0.29) to account for the financial impact of the TranSenda transaction.
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here